Printer Friendly

DU PONT MERCK APPOINTS TWO R&D VICE PRESIDENTS

 DU PONT MERCK APPOINTS TWO R&D VICE PRESIDENTS
 WILMINGTON, Del., April 27 /PRNewswire/ -- The Du Pont Merck


Pharmaceutical Company has appointed two vice presidents in research and development.
 Pieter Timmermans has been appointed vice president, drug discovery. He had previously been executive director, cardiovascular and central nervous system diseases.
 Henry Pan was named vice president, clinical research and development, a newly created post. He joins Du Pont Merck from Bristol-Myers Squibb, where he had been vice president for clinical research.
 "We have assembled a leadership team on which to build our 21st century research and development success," said David W. Martin, executive vice president for research and development.
 Timmermans replaces Robert Taber, who has assumed the task of creating an extramural research and development program as well as leading a strategic review of the company's radiopharmaceuticals research program. Taber headed pharmaceuticals research for the past 10 years and is credited with overseeing Du Pont Merck's successful program to build an R&D pipeline. Timmermans led the team that discovered losartan, the company's antihypertension drug, now in clinical trials.
 Pan will report to John Mullane, senior vice president for drug development, and Timmermans will report to Martin.
 In addition to losartan, Du Pont Merck also has an Alzheimer's disease candidate, "Aviva," in phase three clinical trials. Other compounds in development include those to treat cancer, aid organ transplantation, combat psychosis and treat arthritis. Annual R&D expenditures are about $230 million.
 Du Pont Merck, headquartered in Wilmington, is an independent, worldwide pharmaceutical company established in 1991 by Du Pont (NYSE: DD) and Merck & Co., Inc. (NYSE: MRK). It had 1991 revenue of about $800 million.
 /delval/
 -0- 4/27/92
 /CONTACT: Roger Morris of Du Pont Merck, 302-992-4747/
 (DD MRK) CO: Du Pont Merck Pharmaceutical Company ST: Delaware IN: MTC SU: PER


LJ -- PH014 -- 3037 04/27/92 10:42 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 27, 1992
Words:311
Previous Article:LUBRIZOL REPORTS RECORD FIRST QUARTER EARNINGS
Next Article:DETROIT EDISON ANNOUNCES EARNINGS INCREASE


Related Articles
DU PONT ANNOUNCES MANAGEMENT CHANGES
DU PONT MERCK EXCEEDS FIRST-YEAR SALES GOAL
DU PONT MERCK CEO RECEIVES HONORARY DOCTORATE
DU PONT MERCK, BANYU PLAN JOINT VENTURE FOR JAPAN
MERCK TO LICENSE TRADEMARK AND MARKETING RIGHTS FOR TWO BRANDS TO THE DU PONT MERCK PHARMACEUTICAL COMPANY AND ITS EUROPEAN SUBSIDIARIES
RETIRED DU PONT EXECUTIVE GETS NATIONAL MEDAL OF SCIENCE
DU PONT ANNOUNCES ORGANIZATION CHANGES
DU PONT MERCK NAMES BLANK VP FOR WORLDWIDE MARKETING
DU PONT MERCK HONORS OUTSTANDING SALES ACHIEVEMENTS: DIRECTOR'S CLUB AWARDS
DU PONT MERCK ANNOUNCES PERSONNEL APPOINTMENT

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters